Our approach
At the centre of our approach our next-generation AI platform we built to find novel connections between drugs and diseases. We combine these predictions with in-house expertise to accelerate new treatments through our pipeline to clinical trials and on to patients.
GeN was built at the intersection of Oxford-bred science and deep translational expertise. We are a premier computational chemistry and rodent behavioral pharmacology team dedicated to redefining therapeutics for rare forms of autism.
Over 16 years of rigorous, targeted R&D, our platform has successfully decoded complex neurodevelopmental pathways, culminating in our vital role within the FRAXA Drug Validation Initiative (FRAXA-DVI), worked in PTHS, AS, KS and ASD.
Our team
Patricia Cogram, PhD
Thomas Haak, PhD
